[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ].

The discovery and production of HMGCoA reductase inhibitor and the fundamental research work of the LDL receptor unraveled a receptor-mediated cholesterol homeostasis. HMGCoA reductase inhibitors are the most commonly prescribed class of lipid-lowering drugs in many countries. The decrease of the intracellular cholesterol caused by the inhibitor induces the compensatory increase of LDL receptor protein at liver plasma membrane. The increased receptor promotes LDL catabolism and results in decrease of plasma LDL. Serious side effects involving the liver or muscle are rare. But the risk of myopathy is increased when the drug is used with other hypolipidemic agents. A principle of the treatment of hyperlipidemia, including secondary one associated with diabetes mellitus and renal disease, by HMGCoA reductase is discussed in this review.
AuthorsH Jingami
JournalNihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 52 Issue 12 Pg. 3271-8 (Dec 1994) ISSN: 0047-1852 [Print] JAPAN
PMID7853722 (Publication Type: English Abstract, Journal Article, Review)
Chemical References
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Receptors, LDL
  • mevastatin
  • Cholesterol
  • Lovastatin
  • Animals
  • Cholesterol (metabolism)
  • Cholesterol, LDL (metabolism)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hyperlipoproteinemias (drug therapy, genetics)
  • Lovastatin (analogs & derivatives, pharmacology, therapeutic use)
  • Receptors, LDL (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: